Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • inulin
Anthocyanin + Prebiotic Fiber for Type 2 Diabetes: A 60‑Day Randomised Trial Shows Improved Glucose and LDL
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Anthocyanin + Prebiotic Fiber for Type 2 Diabetes: A 60‑Day Randomised Trial Shows Improved Glucose and LDL

Posted by MedXY By MedXY 08/09/2025
A double‑blind RCT of 60 patients with T2DM found a 60‑day supplement of riceberry anthocyanin plus inulin and rice bran reduced fasting glucose, HbA1c, and LDL‑C versus placebo with high adherence and no safety signals.
Read More
  • Optimizing Post-Operative Outcomes: The Critical Impact of Specialist Cardiology Evaluation in Peri-operative Myocardial Infarction and Injury
  • IVUS Guidance Slashes 1-Year Target Vessel Failure in Complex Bifurcation PCI: Insights from DKCRUSH VIII
  • Mid-Regional Pro-Adrenomedullin (MR-proADM): A Superior Prognostic Sentinel in Transthyretin Cardiac Amyloidosis
  • Optimizing the Synergy: Sequential vs. Concurrent Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer
  • Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in